Stockholm 1 Oct 2019 – iCellate Medical, in collaboration with RCC - Regional Cancer Center Stockholm Gotland and Region Stockholm are proud to announce that the joint observational study at the Diagnostic Center at Södertälje Hospital is now enrolling its first patients. The study consists of two important groups of difficult to diagnose patients who would benefit greatly from new accurate and swift diagnostic tests.
The purpose of the pioneering study is to confirm whether a blood draw will be enough for iCellate to detect eventual tumor cells or fragments that spread cancer in two groups of patients. Could this genetic tests thereby be a useful tool to classify cancer in early stages, even before symptoms occur?
The study consists of patients with Cancer of Unknown Primary origin (CUP) and of patients with serious but non-specific symptoms that may be caused by cancer. For some CUP-patients the primary tumor is hard to determine despite of adequate investigation. Since current treatment decisions to a large extent are based on knowledge of the biology of the primary tumor, it becomes more difficult to determine the best treatment where the primary tumor is unknown. For patients with non-specific symptoms, where cancer is suspected even after a thorough diagnostic investigation, a test helping the physician to decide whether to dismiss a cancer diagnosis or to carry-on the investigation would be of great advantage.
Charlotta Sävblom, MD, PhD, responsible for building up the model of Diagnostic Centers and designated developer of the early cancer detection and screening work at the RCC Stockholm Gotland comments ”It is extremely gratifying that we can launch this initiative to strengthen clinical cancer research in the field of early detection. Scientific advances will rapidly be of benefit for both cancer patients and the health care sector as whole”.
Typically, the two groups of patients included in the study are not easy to diagnose. Before the establishment of the dedicated Diagnostic Centers, these patients were tossed around in the organ-focused healthcare system, where each cancer type is evaluated sequentially, leading to prolonged diagnostic processes, anxiety in patients and in some cases progression of disease. The Diagnostic Centers, with a clear goal that all patients should be diagnosed within one month, using new cutting-edge technologies, benefit these patients immensely.
“Thanks to RCCs innovative and systematic approach to rapidly bring new technology to benefit patients, we were able to fast-track this important initiative. It is exactly these highly specialized, highly structured Diagnostic Centers that are best positioned to determine how to best apply new single cell-based DNA technologies to benefit patients”, says Christer Ericsson, CSO at iCellate Medical.